title: Cysteinyl leukotriene receptor expression in aspirin-sensitive nasal polyposis patients.
abstract: BACKGROUND
  The aim of this study was to detect cysteinyl leukotriene (Cys-LT) receptors in aspirin-sensitive nasal polyposis patients, and compare them with nasal polyposis and chronic rhinosinusitis patients without aspirin sensitivity.
  
  
  METHODS
  The formalin-fixed, paraffin-embedded tissue blocks of a total of 52 patients undergoing endoscopic sinus surgery were reviewed by an experienced head and neck pathologist. Of these 52 cases, there were 22 nasal polyposis cases with aspirin sensitivity, 15 nasal polyposis cases without aspirin sensitivity and 15 chronic rhinosinusitis cases without aspirin sensitivity. Immunohistochemical analyses for Cys-LT(1) receptors were performed with polyclonal rabbit antibody.
  
  
  RESULTS
  Eosinophil receptor intensity levels were 27.68, 21.67, and 14.40, respectively. This was statistically insignificant (p <0.089). Mast cell receptor intensity levels were 8.41, 5.27, and 4.27, respectively. In the aspirin-sensitive group, mast cell receptor intensity was significantly higher when compared to the nasal polyposis and chronic rhinosinusitis group (p < 0.0001 and p < 0.0001, respectively). The difference in Cys-LT(1) receptor immunoreactivity in both eosinophils and mast cells among the 3 groups was also found to be statistically significant (p < 0.001).
  
  
  CONCLUSIONS
  Our study revealed that nasal polyps of aspirin-sensitive patients were infiltrated with eosinophils and mast cells, Cys-LT(1) receptor proportions in these inflammatory cells were found to be higher and Cys-LT(1) receptor immunoreactivity in eosinophils and mast cells was increased.
authors.affiliation: Mardin State Hospital, Gaziantep, Turkey.
authors.forename: Zeki
authors.initials: Z
authors.lastname: Ozen
authors.forename: Semih
authors.initials: S
authors.lastname: Mumbuc
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Sari
authors.forename: Tekin
authors.initials: T
authors.lastname: Baglam
authors.forename: Erkan
authors.initials: E
authors.lastname: Karatas
authors.forename: Muzaffer
authors.initials: M
authors.lastname: Kanlikama
mesh_terms: D001241:Aspirin / Q000009:adverse effects* / Q000276:immunology; D004342:Drug Hypersensitivity / Q000097:blood / Q000453:epidemiology* / Q000276:immunology; D004724:Endoscopy / Q000379:methods; D004804:Eosinophils / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism; D008264:Macrophages / Q000276:immunology / Q000378:metabolism; D008407:Mast Cells / Q000276:immunology / Q000378:metabolism; D008565:Membrane Proteins / Q000276:immunology / Q000378:metabolism*; D009298:Nasal Polyps / Q000453:epidemiology* / Q000378:metabolism* / Q000601:surgery; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism; D018077:Receptors, Leukotriene / Q000276:immunology / Q000378:metabolism*
chemical_list: D008565:Membrane Proteins; D018077:Receptors, Leukotriene; C083169:leukotriene D4 receptor; D001241:Aspirin